COIL.LSE Coiled Therapeutics plc
- Market cap
- GBX 29.4M
- P/E
- -
- P/B
- 0.60x
- ROE
- -138.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is COIL.LSE undervalued?
Graham numberThe Graham number of Coiled Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Coiled Therapeutics plc fundamental analysis
No fundamental analysis for Coiled Therapeutics plc yet.
Coiled Therapeutics plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Coiled Therapeutics plc
Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company's lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, a…
Full company profileCoiled Therapeutics plc financial statements
Coiled Therapeutics plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 200K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 200K | -16.0K | 0.00 |
| Operating Income | -1.63M | -1.93M | -1.12M | -822K |
| EBITDA | -1.63M | -1.93M | -1.16M | -3.36M |
| Net Income | -1.62M | -1.74M | -972K | -3.36M |
| EPS | -0.13 | -0.14 | -0.07 | -0.21 |
| Balance Sheet | ||||
| Total Assets | 7.77M | 6.09M | 5.75M | 2.69M |
| Total Liabilities | 562K | 589K | 862K | 273K |
| Shareholders' Equity | 7.21M | 5.50M | 4.89M | 2.42M |
| Cash & Short-term Investments | 2.32M | 537K | 337K | 78.1K |
| Cash Flow | ||||
| Operating Cash Flow | -1.58M | -1.73M | -784K | -646K |
| Capital Expenditure | 0.00 | 54.0K | 0.00 | 0.00 |
| Free Cash Flow | -1.58M | -1.79M | -784K | -646K |
| Ratios | ||||
| ROE | -22.4% | -31.7% | -19.9% | -138.9% |
| ROA | -20.8% | -28.7% | -16.9% | -124.8% |
| Net Profit Margin | - | -872.3% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Coiled Therapeutics plc dividends
Coiled Therapeutics plc has not paid dividends in the last 4 fiscal years.
Last stock split: 1:10 on Mar 27, 2026.
Who owns Coiled Therapeutics plc
- Insiders 62.38%
- Institutions 7.25%
- Public & others 30.37%
- Shares outstanding 427M
Coiled Therapeutics plc company profile
- Company name
- Coiled Therapeutics plc
- Ticker
- COIL.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 167-169 Great Portland Street, London, United Kingdom, W1W 5PF
- Phone
- 44 20 3918 8633
- Website
- coiledplc.com
About Coiled Therapeutics plc
Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. The company's lead asset is AO-252, a first-in-class, small molecule inhibitor of TACC3, currently in a Phase I clinical trial for advanced solid tumours, including ovarian and prostate cancer. The company also offers a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials. The company is based in London, United Kingdom.
Coiled Therapeutics plc management
4- Dr. Sotirios G. Stergiopoulos M.D., MBEEExecutive Chairman · born 1971
- Mr. Sridhar Vempati MBA, Ph.D.CEO & Director · born 1977
- Ms. Chaemin Lim Ph.D.Chief Technology Officer
- Ms. Robbin Frnka B.S.Chief Clinical Operations